A Study of Dulaglutide (LY2189265) in Children and Adolescents With Type 2 Diabetes
Status:
Active, not recruiting
Trial end date:
2022-01-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics and
pharmacodynamics of the study drug dulaglutide compared to placebo in pediatric participants
with type 2 diabetes. The study duration is approximately 60 weeks.